Sobi

Sobi is a global biopharmaceutical company that develops and delivers medicines for people living with rare and debilitating diseases. Headquartered in Sweden, the company operates in 30 countries and works across the biopharmaceutical industry verticals of rare diseases, haematology, immunology, specialty care and orphan drugs.

The company's scientific work spans protein therapeutics, blood plasma fractionation, recombinant clotting factor development, extended half-life therapies, vitamin research and the drying of sensitive biological materials. A particular focus is haemophilia care, alongside orphan drug development for patient groups with limited treatment options.

Although Sobi was founded in 2010, its origins trace back to the 1930s, giving it more than 90 years of heritage. That history is rooted in curiosity-driven research and a legacy of scientific innovation, and the organisation describes a patient-focused mission for rare disease communities and a culture that values challenges overcome through innovation.